Literature DB >> 25297997

Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses.

Michael Wolferstätter1, Marc Schweneker1, Michaela Späth1, Susanne Lukassen1, Marieken Klingenberg1, Kay Brinkmann1, Ursula Wielert1, Henning Lauterbach1, Hubertus Hochrein1, Paul Chaplin1, Mark Suter2, Jürgen Hausmann3.   

Abstract

UNLABELLED: Double-stranded RNA (dsRNA) is an important molecular pattern associated with viral infection and is detected by various extra- and intracellular recognition molecules. Poxviruses have evolved to avoid producing dsRNA early in infection but generate significant amounts of dsRNA late in infection due to convergent transcription of late genes. Protein kinase R (PKR) is activated by dsRNA and triggers major cellular defenses against viral infection, including protein synthesis shutdown, apoptosis, and type I interferon (IFN-I) production. The poxviral E3 protein binds and sequesters viral dsRNA and is a major antagonist of the PKR pathway. We found that the highly replication-restricted modified vaccinia virus Ankara (MVA) engineered to produce excess amounts of dsRNA early in infection showed enhanced induction of IFN-β in murine and human cells in the presence of an intact E3L gene. IFN-β induction required a minimum overlap length of 300 bp between early complementary transcripts and was strongly PKR dependent. Excess early dsRNA produced by MVA activated PKR early but transiently in murine cells and induced enhanced systemic levels of IFN-α, IFN-γ, and other cytokines and chemokines in mice in a largely PKR-dependent manner. Replication-competent chorioallantois vaccinia virus Ankara (CVA) generating excess early dsRNA also enhanced IFN-I production and was apathogenic in mice even at very high doses but showed no in vitro host range defect. Thus, genetically adjuvanting MVA and CVA to generate excess early dsRNA is an effective method to enhance innate immune stimulation by orthopoxvirus vectors and to attenuate replicating vaccinia virus in vivo. IMPORTANCE: Efficient cellular sensing of pathogen-specific components, including double-stranded RNA (dsRNA), is an important prerequisite of an effective antiviral immune response. The prototype poxvirus vaccinia virus (VACV) and its derivative modified vaccinia virus Ankara (MVA) produce dsRNA as a by-product of viral transcription. We found that inhibition of cellular dsRNA recognition established by the virus-encoded proteins E3 and K3 can be overcome by directing viral overexpression of dsRNA early in infection without compromising replication of MVA in permissive cells. Early dsRNA induced transient activation of the cellular dsRNA sensor protein kinase R (PKR), resulting in enhanced production of interferons and cytokines in cells and mice. Enhancing the capacity of MVA to activate the innate immune system is an important approach to further improve the immunogenicity of this promising vaccine vector.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25297997      PMCID: PMC4249137          DOI: 10.1128/JVI.02082-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

Review 1.  IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.

Authors:  Jeffrey S Kennedy; Richard N Greenberg
Journal:  Expert Rev Vaccines       Date:  2009-01       Impact factor: 5.217

2.  Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara.

Authors:  Christine Meisinger-Henschel; Michaela Schmidt; Susanne Lukassen; Burkhard Linke; Lutz Krause; Sebastian Konietzny; Alexander Goesmann; Paul Howley; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Gen Virol       Date:  2007-12       Impact factor: 3.891

3.  Antagonizing activity of vaccinia virus E3L against human interferons in Huh7 cells.

Authors:  Janilyn Arsenio; Yvon Deschambault; Jingxin Cao
Journal:  Virology       Date:  2008-05-27       Impact factor: 3.616

4.  Induction of protein kinase PKR-dependent activation of interferon regulatory factor 3 by vaccinia virus occurs through adapter IPS-1 signaling.

Authors:  Ping Zhang; Charles E Samuel
Journal:  J Biol Chem       Date:  2008-10-15       Impact factor: 5.157

5.  West Nile virus-induced interferon production is mediated by the double-stranded RNA-dependent protein kinase PKR.

Authors:  Felicia D Gilfoy; Peter W Mason
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

6.  Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes.

Authors:  Erika Assarsson; Jason A Greenbaum; Magnus Sundström; Lana Schaffer; Jennifer A Hammond; Valerie Pasquetto; Carla Oseroff; R Curtis Hendrickson; Elliot J Lefkowitz; David C Tscharke; John Sidney; Howard M Grey; Steven R Head; Bjoern Peters; Alessandro Sette
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-01       Impact factor: 11.205

7.  The RNA-activated protein kinase enhances the induction of interferon-beta and apoptosis mediated by cytoplasmic RNA sensors.

Authors:  Christopher S McAllister; Charles E Samuel
Journal:  J Biol Chem       Date:  2008-11-20       Impact factor: 5.157

8.  Identification from diverse mammalian poxviruses of host-range regulatory genes functioning equivalently to vaccinia virus C7L.

Authors:  Xiangzhi Meng; Jie Chao; Yan Xiang
Journal:  Virology       Date:  2007-12-03       Impact factor: 3.616

Review 9.  Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action.

Authors:  M A García; J Gil; I Ventoso; S Guerra; E Domingo; C Rivas; M Esteban
Journal:  Microbiol Mol Biol Rev       Date:  2006-12       Impact factor: 11.056

10.  Inhibition of IkappaB kinase by vaccinia virus virulence factor B14.

Authors:  Ron A-J Chen; Grigory Ryzhakov; Samantha Cooray; Felix Randow; Geoffrey L Smith
Journal:  PLoS Pathog       Date:  2008-02-08       Impact factor: 6.823

View more
  12 in total

Review 1.  Discrimination of Self and Non-Self Ribonucleic Acids.

Authors:  Anna Gebhardt; Beatrice T Laudenbach; Andreas Pichlmair
Journal:  J Interferon Cytokine Res       Date:  2017-05       Impact factor: 2.607

Review 2.  Ebola virus disease candidate vaccines under evaluation in clinical trials.

Authors:  Karen A Martins; Peter B Jahrling; Sina Bavari; Jens H Kuhn
Journal:  Expert Rev Vaccines       Date:  2016-05-27       Impact factor: 5.217

3.  Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.

Authors:  Marc Schweneker; Andrea S Laimbacher; Gert Zimmer; Susanne Wagner; Elisabeth M Schraner; Michael Wolferstätter; Marieken Klingenberg; Ulrike Dirmeier; Robin Steigerwald; Henning Lauterbach; Hubertus Hochrein; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

4.  Pattern Recognition Receptors of Nucleic Acids Can Cause Sublethal Activation of the Mitochondrial Apoptosis Pathway during Viral Infection.

Authors:  Sylwia Gradzka-Boberda; Ian E Gentle; Georg Häcker
Journal:  J Virol       Date:  2022-09-07       Impact factor: 6.549

5.  cFLIPL Interrupts IRF3-CBP-DNA Interactions To Inhibit IRF3-Driven Transcription.

Authors:  Lauren T Gates; Joanna L Shisler
Journal:  J Immunol       Date:  2016-06-24       Impact factor: 5.422

6.  E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.

Authors:  Asisa Volz; Sylvia Jany; Astrid Freudenstein; Markus Lantermann; Holger Ludwig; Gerd Sutter
Journal:  Viruses       Date:  2018-01-04       Impact factor: 5.048

Review 7.  Poxviral Strategies to Overcome Host Cell Apoptosis.

Authors:  Chathura D Suraweera; Mark G Hinds; Marc Kvansakul
Journal:  Pathogens       Date:  2020-12-23

8.  Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures.

Authors:  Jessamine E Hazlewood; Troy Dumenil; Thuy T Le; Andrii Slonchak; Stephen H Kazakoff; Ann-Marie Patch; Lesley-Ann Gray; Paul M Howley; Liang Liu; John D Hayball; Kexin Yan; Daniel J Rawle; Natalie A Prow; Andreas Suhrbier
Journal:  PLoS Pathog       Date:  2021-01-13       Impact factor: 6.823

Review 9.  Mucosal immunity and tRNA, tRF, and tiRNA.

Authors:  Yueying Chen; Jun Shen
Journal:  J Mol Med (Berl)       Date:  2020-11-16       Impact factor: 4.599

10.  Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses.

Authors:  María Pía Holgado; Juliana Falivene; Cynthia Maeto; Micaela Amigo; María Fernanda Pascutti; María Belén Vecchione; Andrea Bruttomesso; Gabriela Calamante; María Paula Del Médico-Zajac; María Magdalena Gherardi
Journal:  Viruses       Date:  2016-05-23       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.